Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen O'Quinn

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Headache|May 16, 2002
Migraine, Midrin, and ImitrexSteve Landy, Mary Richardson, Stephen O'Quinn
Journal of Patient-Reported Outcomes|April 1, 2026
Caregiver-perceived behavioral challenges in fragile X syndrome and implications for measuring treatment benefit in clinical trialsElizabeth Merikle, Nancy Tich, Terri Sebree, et al.
Mayo Clinic Proceedings|October 9, 2003
Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studiesPaul Winner, Lisa K Mannix, D Gayla Putnam, et al.
Clinical Therapeutics|May 23, 2002
The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteersKaty H P Moore, Philip T Leese, Scott McNeal, et al.
Journal of Neurodevelopmental Disorders|January 9, 2023
Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatmentJoseph M Palumbo, Brian F Thomas, Dejan Budimirovic, et al.
Journal of Neurodevelopmental Disorders|November 26, 2022
A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)Elizabeth Berry-Kravis, Randi Hagerman, Dejan Budimirovic, et al.
Journal of Neurodevelopmental Disorders|November 19, 2025
Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension studyElizabeth Berry-Kravis, Randi Hagerman, Jonathan Cohen, et al.
Frontiers in Neuroscience|January 29, 2026
Correction: An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's diseaseChristopher L Reading, Jiayan Yan, Marcia A Testa, et al.
Frontiers in Neuroscience|May 19, 2025
An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's diseaseChristopher L Reading, Jiayan Yan, Marcia A Testa, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Headache|May 16, 2002
Migraine, Midrin, and ImitrexSteve Landy, Mary Richardson, Stephen O'Quinn
Journal of Patient-Reported Outcomes|April 1, 2026
Caregiver-perceived behavioral challenges in fragile X syndrome and implications for measuring treatment benefit in clinical trialsElizabeth Merikle, Nancy Tich, Terri Sebree, et al.
Mayo Clinic Proceedings|October 9, 2003
Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studiesPaul Winner, Lisa K Mannix, D Gayla Putnam, et al.
Clinical Therapeutics|May 23, 2002
The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteersKaty H P Moore, Philip T Leese, Scott McNeal, et al.
Journal of Neurodevelopmental Disorders|January 9, 2023
Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatmentJoseph M Palumbo, Brian F Thomas, Dejan Budimirovic, et al.
Journal of Neurodevelopmental Disorders|November 26, 2022
A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)Elizabeth Berry-Kravis, Randi Hagerman, Dejan Budimirovic, et al.
Journal of Neurodevelopmental Disorders|November 19, 2025
Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension studyElizabeth Berry-Kravis, Randi Hagerman, Jonathan Cohen, et al.
Frontiers in Neuroscience|January 29, 2026
Correction: An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's diseaseChristopher L Reading, Jiayan Yan, Marcia A Testa, et al.
Frontiers in Neuroscience|May 19, 2025
An exploratory analysis of bezisterim treatment associated with decreased biological age acceleration, and improved clinical measure and biomarker changes in mild-to-moderate probable Alzheimer's diseaseChristopher L Reading, Jiayan Yan, Marcia A Testa, et al.
Pageof 1